BlossomHill Therapeutics (BLSM) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BlossomHill Therapeutics is the larger company by market cap ($526.2 million vs $523.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLSM | OCS |
|---|---|---|
| Share price | $16.56 | $8.51 |
| Market cap | $526.20M | $523.81M |
| 1-day change | -0.33% | +0.06% |
| YTD return | — | -57.44% |
| 1-year return | — | -55.40% |
| 5-year return | — | -13.44% |
| EPS (TTM) | $-4.70 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.99 | $34.48 |
| 52-week low | $15.25 | $8.30 |
| Distance from 52-week high | -40.85% | -75.33% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +113.83% | +329.04% |
| Average volume | 263.46K | 258.13K |
| Shares outstanding | 31.78M | 61.59M |
| Employees | 69 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BlossomHill Therapeutics
BLSM stock →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
BLSM vs OCS FAQ
Which is bigger, BlossomHill Therapeutics or Oculis?
BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $526.20M compared with $523.81M for Oculis (OCS).
Are BlossomHill Therapeutics and Oculis in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.